EC Number |
Substrates |
Organism |
Products |
Reversibility |
---|
1.14.11.29 | DLDLEMLAPYIPMD + 2-oxoglutarate + O2 |
Vmax is 100% of the activity with DLDLEMLAPYIPMDDDFQL |
Homo sapiens |
DLDLEMLA-((4R)-4-hydroxy-L-proline)-YIPMD + succinate + CO2 |
- |
? |
1.14.11.29 | DLDLEMLAPYIPMDD + 2-oxoglutarate + O2 |
Vmax is 100% of the activity with DLDLEMLAPYIPMDDDFQL |
Homo sapiens |
DLDLEMLA-((4R)-4-hydroxy-L-proline)-YIPMDD + succinate + CO2 |
- |
? |
1.14.11.29 | DLDLEMLAPYIPMDDDF + 2-oxoglutarate + O2 |
Vmax is 100% of the activity with DLDLEMLAPYIPMDDDFQL |
Homo sapiens |
DLDLEMLA-((4R)-4-hydroxy-L-proline)-YIPMDDDF + succinate + CO2 |
- |
? |
1.14.11.29 | DLDLEMLAPYIPMDDDFQL + 2-oxoglutarate + O2 |
- |
Homo sapiens |
DLDLEMLA-((4R)-4-hydroxy-L-proline)-YIPMDDDFQL + succinate + CO2 |
- |
? |
1.14.11.29 | DLDLEMLAPYIPMDDDFQL + 2-oxoglutarate + O2 |
peptide derived from HIF-1alpha |
Homo sapiens |
DLDLEMLA-((4R)-4-hydroxy-L-proline)-YIPMDDDFQL + succinate + CO2 |
- |
? |
1.14.11.29 | DLDLEMLAPYIPMDDDFQL + 2-oxoglutarate + O2 |
substrate derived from C-terminal oxygen-dependent degradation domain |
Homo sapiens |
DLDLEMLA-((4R)-4-hydroxy-L-proline)-YIPMDDDFQL + succinate + CO2 |
- |
? |
1.14.11.29 | DLDLEMLAPYIPMDDDFQL + 2-oxoglutarate + O2 |
- |
Homo sapiens |
? |
- |
? |
1.14.11.29 | DLDLEMLAPYIPMDDDFQL + 2-oxoglutarate + O2 |
- |
Mus musculus |
? |
- |
? |
1.14.11.29 | DLDLEMLAPYIPMDDDFQLRSFDQ + 2-oxoglutarate + O2 |
Vmax is 100% of the activity with DLDLEMLAPYIPMDDDFQL |
Homo sapiens |
DLDLEMLA-((4R)-4-hydroxy-L-proline)-YIPMDDDFQLRSFDQ + succinate + CO2 |
- |
? |
1.14.11.29 | DLDLEMLAPYIPTIISLDF + 2-oxoglutarate + O2 |
hybrid substrate derived from C-terminal and N-terminal oxygen-dependent degradation domain |
Homo sapiens |
DLDLEMLA-((4R)-4-hydroxy-L-proline)-YIPTIISLDF + succinate + CO2 |
- |
? |